Q-omics provides the consensus-scored NOSTRIN profile across patient tissues and cancer cell-line models. NOSTRIN expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NOSTRIN is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, NOSTRIN protein abundance shows 27,321 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where NOSTRIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOSTRIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOSTRIN survival associations across molecular data types. NOSTRIN RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOSTRIN RNA expression–survival associations across cancer types. High NOSTRIN expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, HNSC, KIRP and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NOSTRIN RNA expression.
This table summarizes NOSTRIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NOSTRIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOSTRIN shows lower tumor expression in KICH, BLCA, LUSC, LUAD, KIRP and HNSC. The KICH box plot shows higher NOSTRIN RNA expression in normal versus tumor tissue (log2 FC = −2.906, t-test p < 0.001).
This table shows molecular features associated with NOSTRIN in patient tissues and cancer cell lines. In patient samples, NOSTRIN shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOSTRIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
